Investigating biomarkers of Staphylococcus aureus bacteremia in patients - School of Pharmacy

The Centers for Disease Control identifies methicillin-resistant S. aureus (MRSA) as a serious health threat with greater than 100,000 invasive infections and 20,000 patient deaths annually in the United States. Despite recent advancements in available treatment options for methicillin-sensitive S.

Microorganisms, Free Full-Text

Biofilm and virulence production during antimicrobial exposures - School of Pharmacy

Current Paradigms of Combination Therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients? - Abstract - Europe PMC

Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study - The Lancet Infectious Diseases

School of Pharmacy and Pharmaceutical Sciences 2020-21 Annual Report by BinghamtonU - Issuu

Antimicrobial resistance - Wikipedia

How to investigate and manage a patient with a Staphylococcus aureus bacteraemia

Full article: Contemporary pharmacologic treatments of MRSA for hospitalized adults: rationale for vancomycin versus non-vancomycin therapies as first line agents

Examining the clinical impact of rapid multiplex polymerase chain reaction‐based diagnostic testing for bloodstream infections in a national cohort of the Veterans Health Administration - Britt - 2023 - Pharmacotherapy: The Journal

Implementing a hospital-wide protocol for Staphylococcus aureus bacteremia